HAPLO-iPS

# D7.3: Report on Database for inclusion of clinical trials and their follow-up in hPSCreg

## Table of Contents


**1. EXECUTIVE SUMMARY ..... 2**

**2. INTRODUCTION ..... 2**

**3. DATABASE CONTENT ..... 2**

3.1 DATABASE OF CLINICAL TRIALS ..... 3
3.2 AI-BASED TRIAL FILTERING PLATFORM ..... 3
3.3 HPSCREG LINK ..... 4
3.4 OUTLOOK ..... 5


## List of Figures


Figure 1. Trial filtering and identification platform

Figure 2. Data flow between centralized LIFCU registry, other resources and user


## List of Annexes


Annex 1. Clinical trials table

## 1. Executive Summary

The number of clinical trials based on pluripotent stem cells (PSC) has increased steadily. As of October 2026, 255 trials have been initiated. Some trials are now in phase 3, and first marketing approvals were granted in Japan for two applications (Parkinsons Disease and Heart Failure). An overview of induced PSC (iPSC) – based clinical trials is relevant for Haplo-iPS as it reflects the current status. However, the use of haplotypes for patient selection and other hypoimmunogenic approaches cannot be deducted. As the Registry hPSCreg (www.hpscreg.eu) maintains a clinical trial database for human PSC – based trials, the harmonization of the information gathered within Haplo-iPS and hPSCreg was a goal of the work.

### Introduction

The number of iPSC – based trials increases annually. However, information on these trials is difficult to find, scattered around databases and hidden beyond a 100.000 – fold dominance of non-PSC trials.

An overview of existing clinical studies using PSC – lines are relevant to assess the scope of use of haplotyped iPSC – lines, fully allogenic lines and autologous lines. In addition, given the lagging behind of EU-based clinical trials (as compared to the USA, China, Japan and others), decisions on new clinical development targets can be based on existing targets, cell types used for therapy and patient groups. It also informes about players and sponsors in the field, which may be interested in investing in Europe to develop this field. In addition, knowledge about the dynamics of clinical trials development provides arguments to invest into this field and enhance the use of available European resources.

Here, we provide an updated overview of clinical trials conducted globally. We also present a platform allowing for automated, large language model - based discovery of clinical trials using iPSC – lines. This tool can be used to update and harmonize the clinical trial database in hPSCreg.

## 2. Database Content

### 2.1 Database of clinical trials


A database of clinical trials was established (**Annex 1**). It includes all PSC – based (iPSC and embryonic stem cell lines) clinical trials conducted globally since 2010, when the first trial was initiated in the USA. The table includes information n the source cell type (iPSC, ESC), target disease, therapeutic cell type, the study title also indicating allogenic or autologous use, start date and country where the study is conducted. The two applications already approved for marketing in Japan are included, as legally it is still a clinical study format.
The clinical trial table lists more clinical studies than listed in publications on this topic (1-3).

## 2.2 AI-based trial filtering platform

We developed a platform that leverages large language models (LLM) for automated classification of clinical trial data related to iPSC and ESC. The platform was validated within a scientific exchange of a young scientist (STSM) in the frame of Haplo-iPS.

The platform is able to identify the small number of PSC – based trials among more than 100 Mio trials in the public domain (only 0.016% of trials are PSC – trials). **Figure 1** shows the overall classification workflow for PSC – based trials.


**Figure 1**. Trial filtering and identification platform. The workflow consists of the elements text processing, domain term screening, entity recognition and SVM – based classification.




Using this model, accuracy of over 95% is achieved in selecting PSC – based trials, with 100% sensitivity.

The data derived with the tool are real world data (RWD) which can be analyzed using different modules. **Figure 2** shows clinical phase composition of ongoing trials plotted against clinical phenotype areas.

**Figure 2.** Clinical phase composition data by clinical feature category show dominance in ocular targeting cell therapies, where trials are most numerous and advanced. This clinical feature class is followed by neurological and cardiac applications (n=196 trials).




## 2.3 hPSCreg link

The stand-alone central resource hPSCreg is an EU – funded database / registry for human pluripotent stem cell lines. The Registry annotated the lines with research projects conducted with each line, and in addition maintains a clinical trial database. This database s sporadically updated and links cell lines used in these trials to cell lines registered in hPSCreg, if this information is available. Thus, using a unique identifier issued by the Registry for each cell line, findability of trials associated with specific cell lines is possible.

This capability allows for linking clinical trials conducted with haplotyped iPSC – lines, haplotyped resources of starting material such as cord blood banks, donors of the starting material. In WG 3.2 of Haplo-iPS, we have developed a data scheme to integrate such haplotyped lines intended for clinical use into hPSCreg. This integration would allow the above described information pathway.

The clinical trial database presented here will be harmonized with the clinical trial database in hPSCreg to make core information accessible and findable via this platform.

This harmonization will be implemented via hPSCreg cell line identifiers of lines intended for clinical use (LIFCU). The LIFCU identifiers will be used in the clinical trial database (Annex 1), allowing findability of associated information. The clinical trial database is updated regularly and identifier annotations updated.

### 2.4 Outlook

A clinical trial database was established for trials using hPSC as source material. Using an automated, LLM – based platform, this database can be updated regularly. The database will be maintained as a stand alone resource. To assuce access to data and interoperability, a matching algorithm needs to be established based on the hPSCreg cell line identifier. As clinical trials are based on LIFCU – lines, the LIFCU data scheme presented in D3.2 must be implemented in hPSCreg. Data hosted by the clinical trial databases, the LIFCU resource in hPSCreg and starting material resources such as cord blood banks and bone marrow donor registries become interoperable and data findable and accessible.

REFERENCES


1. Kirkeby A, Main H, Carpenter M. Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update. Cell Stem Cell. 2025 Jan 2;32(1):10-37. doi: 10.1016/j.stem.2024.12.005. Erratum in: Cell Stem Cell. 2025 Feb 6;32(2):329-331. doi: 10.1016/j.stem.2025.01.003. PMID: 39753110.
2. Kobold S, Bultjer N, Stacey G, Mueller SC, Kurtz A, Mah N. History and current status of clinical studies using human pluripotent stem cells. Stem Cell Reports. 2023 Aug 8;18(8):1592-1598. doi: 10.1016/j.stemcr.2023.03.005. Epub 2023 Apr 6. PMID: 37028422; PMCID: PMC10444540.
3. Thomas L, Rana S, Duong A, Kirkham AM, Shorr R, Maganti H, Seftel M, Allan DS. The emerging promise of induced pluripotent stem cells in clinical studies: a systematic scoping review of the literature and registered clinical trials. Cytotherapy. 2026 Jan;28(1):101985. doi: 10.1016/j.jcyt.2025.09.008. Epub 2025 Sep 26. PMID: 41160002.

ANNEX 1. Clinical trials table (as of 10/2026 including hESC -based)

| No. | Title (public title) | Starting material (iPSC, ESC, other) | Target disease group | Therapeutic cell (neuronal, T-cell, NK…) | Country | Start date |
|---|---|---|---|---|---|---|
| 1 | A Confirmatory Study of Allogeneic iPSC-derived Dopaminergic Progenitor Cells (Raguneprocel) in Patients with Parkinson's Disease (Post-marketing Clinical Study) | iPSC | PD/nervous system | dopaminergic progenitor cell | Japan | 2026-07-24 |
| 2 | SAFE-iPS - France's First Hospital-based Platform for the Production of Induced Pluripotent Stem Cells for the Regenerative Medicine of the Future SAFE-iPS | iPSC | n/a | none – no cell product administered (iPSC generation / disease modelling) | France | 2026-11 |
| 3 | A randomized, double-blind, placebo-controlled clinical study on intra-articular injection of induced pluripotent stem cell-derived chondrospheroids (MIUChon, Minimal Injectable Unit Chondrospheroid) in patients with knee osteoarthritis | iPSC | Musculoskeletal/cartilage | chondrospheroids | South Korea | 2026-09-01 |
| 4 | A Pivotal Clinical Trial of human induced pluripotent stem cell-derived cardiomyocytes injection (HiCM-188) for the treatment of Advanced Heart Failure(NYHA III-IV) | iPSC | Heart | cardiomyocytes | China | 2026-05-14 |
| 5 | OSC Co-culture for Rescue IVM of Human GV Oocytes OSC-rIVM | iPSC | Ovary | ovarian support cell (in vitro co-culture) | Vietnam | 2026-06 |
| 6 | Production of Stem Cells for the Generation of Pancreatic Cells | iPSC | Diabetes/islets | none – no cell product administered (iPSC generation / disease modelling) | Italy | 2026-03-01 |
| 7 | A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy | iPSC | Diabetes/islets | islet cell | China | 2026-03-16 |
| 8 | Exploratory Clinical Study of iPSC-Derived Exosomes (GD-iExo-001) in Scarless Wound Healing | iPSC | Immune System/skin | Exosomes | China | 2026-01-30 |
| 9 | GENES AND AUTISM - Induced Pluripotent Stem Cells | iPSC | Autism/nervous system | none – no cell product administered (iPSC generation / disease modelling) | France | 2026-12-01 |
| 10 | Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease | ESC | PD/nervous system | dopaminergic progenitor cell | Iran | 2025-08-01 |
| 11 | An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells | iPSC | Diabetes/islets | pancreatic islet cell | China | 2025-10-17 |

| | | | | | | |
|---|---|---|---|---|---|---|
| | (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events | | | | | |
| 12 | Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Ischemic Heart Failure | iPSC | Heart | cardiomyocytes | China | 2024-11-04 |
| 13 | Treatment of children epileptic encephalopathy with iPSC derived exosomes (GD-iExo-002): a clinical exploratory study | iPSC | Brain/nervous system | Exosomes | China | 2024-03-25 |
| 14 | Efficacy and Safety of Human Embryonic Stem Cell Derived Mesenchymal Stromal Cells for Acute Graft-versus-Host Disease in Children | ESC | Immune System/Blood | mesenchymal stroma cell | China | |
| 15 | Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease | iPSC | PD/nervous system | dopaminergic progenitor cell | China | 2026-08-03 |
| 16 | Engineering Immune Organoids to Study Pediatric Cancer (IMMUNEORGANOID) | iPSC | Neoplasia/solid | none – no cell product administered (iPSC generation / disease modelling) | France | 2023-05-12 |
| 17 | Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells(iPSC) (MOSAIC) | iPSC | Lung | none – no cell product administered (iPSC generation / disease modelling) | France | 2022-11-29 |
| 18 | Preparation of IPSC for Cell Gene Editing for the Treatment of AATD | iPSC | Liver | none – no cell product administered (iPSC generation / disease modelling) | Italy | 2025-01-15 |
| 19 | Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs) (hiPSSS) | iPSC | Immune System/skin | none – no cell product administered (iPSC generation / disease modelling) | France | 2026-09 |
| 20 | Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Acute Ischemic Stroke | iPSC | Heart | Endothelial Progenitor Cell | China | 2023-08-24 |
| 21 | Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Critical Limb Ischemia | iPSC | Vasculature | Endothelial Progenitor Cell | China | 2024-04 |
| 22 | An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease | iPSC | PD/nervous system | dopaminergic progenitor cell | China | 2025-03-01 |
| 23 | A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis (RECLAIM-LN) | iPSC | Immune System/Blood | T cell | USA | 2026-07-27 |

| | | | | | | |
|---|---|---|---|---|---|---|
| 24 | iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study | iPSC | Nervous system | none – no cell product administered (iPSC-based drug repurposing) | Japan | 2019-03-19 |
| 25 | Testing a New Gold Nanoparticle-Based Lithium Delivery Method for Bipolar Disorder in Laboratory Models (GLAD) | iPSC | Brain/nervous system | none – no cell product administered (iPSC generation / disease modelling) | Italy | 2026-10-01 |
| 26 | Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia | iPSC | Neoplasia/blood | natural killer cell | China | 2023-09-10 |
| 27 | Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care Settings (HEALTH) | iPSC | n/a | n/a | USA | 2025-10-06 |
| 28 | A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT | iPSC | Immune System/Blood | natural killer cell | China | 2024-07-15 |
| 29 | First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma | iPSC | Neoplasia/solid Brain | natural killer cell | USA | 2026-04-23 |
| 30 | iPS Cells of Patients for Models of Retinal Dystrophies (RETIPS) | iPSC | Eye | none – no cell product administered (iPSC generation / disease modelling) | France | 2014-11-03 |
| 31 | Safety and Tolerability Study of a Novel Bioartificial Liver in Liver Failure and Small-for-Size Syndrome | iPSC (CiPSC) | Liver | hepatocyte (extracorporeal bioartificial liver) | China | 2025-12-01 |
| 32 | Benefits of Epithelial Repair in COPD by Induced Pluripotent Stem Cells (iPS) (RepCOPDiPS) | iPSC | Lung | none – no cell product administered (iPSC generation / disease modelling) | France | 2025-02-19 |
| 33 | GENES AND AUTISM - Induced Pluripotent Stem Cells (IPSC) | iPSC | Autism/nervous system | none – no cell product administered (iPSC generation / disease modelling) | France | 2026-12-01 |
| 34 | Safety and Preliminary Efficacy of iEVs Injection in Treating Lateral Epicondylitis of Humerus (iEVs) | iPSC | Musculoskeletal | Extracellular Vesicles | China | 2023-07-01 |
| 35 | Phase I Study of Stereotactic Intracerebral Transplantation of Allogeneic iPSC-derived Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for Multiple System Atrophy, Parkinsonian Variant (MSA-P) | iPSC | Brain/nervous system | dopaminergic neural progenitor cell | China | 2026-06-15 |
| 36 | A Pivotal Clinical Trial of Human iPSC-derived Cardiomyocytes Injection (HiCM-188) for Advanced Heart Failure (NYHA III-IV) (REVIVE-HEART) | iPSC | Heart | cardiomyocytes | China | 2026-04-30 |

| | | | | | | |
|---|---|---|---|---|---|---|
| 37 | hiPSC-CMs-loaded Chitosan Patch (HiCM-188 Chitosan Patch) in patients undergoing CABG | iPSC | Heart | cardiomyocytes (on chitosan patch) | China | 2026-10-20 |
| 38 | HiCM-188 Cell Therapy in Adults With Advanced Heart Failure | iPSC | Heart | cardiomyocytes | USA | 2026-09 |
| 39 | Safety and Tolerability Study of a Novel Bioartificial Liver | iPSC (CiPSC) | Liver | hepatocyte (extracorporeal bioartificial liver) | China | 2025-12-01 |
| 40 | BCT301 in Treating Refractory/ | iPSC (CiPSC) | Immune System | T cell (anti-CD19 CAR-iT) | China | 2026-10 |
| 41 | HiSCs in the Treatment of Rheumatoid Arthritis | iPSC | Musculoskeletal/immune system | hiSC (immunomodulatory cell; lineage not specified) | China | 2025-05-01 |
| 42 | Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Patients With Refractory Neuroendocrine Tumor | iPSC | Neoplasia/solid | natural killer cell | China | 2026-02-20 |
| 43 | Stereotactic Intracerebral Injection Of Allogenic IPSC-DAPs In Patients With Parkinson's Disease | iPSC | PD/nervous system | dopaminergic neural progenitor cell | China | 2026-02-28 |
| 44 | This Clinical Trial Is Designed To Evaluate The Safety, Tolerability, Feasibility And Preliminary Efficacy Of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) In Patients With Parkinson's Disease. | iPSC | PD/nervous system | dopaminergic progenitor cell | China | 2025-10-01 |
| 45 | First In Human Randomised Trial Of Rincell-1 In Adults With A Cochlear Implant | ESC | Ear | otic neural progenitor cell | UK | 2025-10-01 |
| 46 | A Prospective Study On Induced Pluripotent Stem Cell-Derived Exosomes For The Treatment Of Diabetic Peripheral Neuropathy | iPSC | Diabetes/nervous system | Exosomes | China | 2025-09-08 |
| 47 | Phase IIa Clinical Study Of Human Neural Precursor Cell (HNPC) Transplantation For Ischemic Brain Injury —— A Phase IIa Clinical Study To Evaluate The Safety, Tolerability, And Efficacy Of HNPC01 Injection Derived From Human Induced Pluripotent Stem Cells In Improving Hemiplegic Sequelae Of Ischemic Stroke | iPSC | Heart | Human Neural Precursor Cell | China | 2025-06-10 |
| 48 | The Safety, Tolerability And Preliminary Efficacy Of Derived Motor Neuron Progenitor Cells (XS228CN) In Subjects With Amyotrophic Lateral Sclerosis | iPSC | Nervous system | Motor Neuron Progenitor Cells | China | 2025-09-15 |

| | | | | | | |
|---|---|---|---|---|---|---|
| 49 | Safety And Early Efficacy Of IPSC-Derived Motor Neuron Progenitor Cells (XS228) In Subacute Spinal Cord Injury: A Phase I Trial | iPSC | Spinal cord/nervous system | Motor Neuron Progenitor Cells | China | 2025-07-02 |
| 50 | The Safety, Feasibility And Efficacy Of NouvNeu001 For Parkinson's Disease | iPSC | PD/nervous system | dopaminergic progenitor cell | | 2025-06-30 |
| 51 | A Trial To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NCR201 In The Treatment Of Subjects With Parkinson's Disease | iPSC | PD/nervous system | dopaminergic neural precursor cell | China | 2025-06-06 |
| 52 | A Study Of IMSC For The Prevention Of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation | iPSC | Immune System/Blood | mesenchymal stroma cell | China | 2025-06-01 |
| 53 | Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease | iPSC | PD/nervous system | dopaminergic neural progenitor cell | China | 2025-09-22 |
| 54 | Clinical Study On The Improvement Of The Treatment Effect Of Nasal Spray Of Exosomes Derived From Induced Pluripotent Stem Cells On Autistic Children | iPSC | Autism/nervous system | exosomes | China | 2025-04-16 |
| 55 | Clinical Study Treating Patients With Knee Arthritis By Injecting Them With Stem Cell-Type Cartilage Cells | iPSC | Musculoskeletal/cartilage | chondrospheroids | Korea | 2025-04-17 |
| 56 | Induced Pluripotent Stem Cells-Derived Small Extracellular Vesicles May Promote Neurological Function And Improve Cognitive Impairment In Acute Ischemic Stroke Patients | iPSC | Heart | Extracellular Vesicles | China | 2025-03-07 |
| 57 | A Study Of NCR100 Injection For The Treatment Of Knee Osteoarthritis( KOA) | iPSC | Musculoskeletal/cartilage | mesenchymal stroma cell | China | 2025-02-20 |
| 58 | Safety And Efficacy Of IMM01-STEM Against Placebo On Muscle Performance In Seniors With Obesity And Muscle Weakness | ESC | Musculoskeletal | | | 2024-12-19 |
| 59 | A Trial To Evaluate The Safety And Efficacy Of NCR300 In Preventing Recurrence Of Acute Myeloid Leukemia(AML) After Transplantation | iPSC | Neoplasia/blood | natural killer cell | China | 2024-06-30 |
| 60 | Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases | iPSC (CiPSC) | Immune System/Blood | Anti-CD19 CAR-iT Cells | China | 2025-12-11 |

| | | | | | | |
|---|---|---|---|---|---|---|
| 61 | A phase I/II study of endocardial delivery for myocardial regeneration using allogeneic iPSC-derived cardiomyocyte spheroids for heart failure with systolic dysfunction | iPSC | Heart | iPSC-derived cardiomyocyte spheroids | Japan | 2026-01-01 |
| 62 | Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease | iPSC | PD/nervous system | dopaminergic neural progenitor cell | China | 2026-02-28 |
| 63 | Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease | iPSC | PD/nervous system | dopaminergic neural progenitor cell | China | 2025-09-22 |
| 64 | The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease | iPSC | PD/nervous system | dopaminergic neural progenitor cell | China | 2025-08-05 |
| 65 | A Study of GD007 (Human iPSC-Exosome Liquid Dressing) for Safety and Dose-Finding in Moderate-Severe Intrauterine Adhesions | iPSC | Uterus | Exosomes | China | 2025-05-04 |
| 66 | Treatment of Moyamoya Disease With iPSC-derived Exosomes | iPSC | Vasculature | Extracellular Vesicles | China | 2025-05-26 |
| 67 | Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial | iPSC | Spinal cord/nervous system | Motor Neuron Progenitor Cells | China | 2028-05-25 |
| 68 | Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial | iPSC | Spinal cord/nervous system | Motor Neuron Progenitor Cells | China | 2025-07-02 |
| 69 | IPSC-CMs Combined with LVAD or CABG for the Treatment of Heart Failure | iPSC | Heart | Cardiomyocytes | USA | 2025-03-01 |
| 70 | Clinical study on the improvement of the treatment effect of nasal spray of exosomes derived from induced pluripotent stem cells on autistic children | iPSC | Autism/nervous system | Exosomes | China | 2025-04-16 |
| 71 | Clinical Trial of Human Neural Precursor Cell (hNPC) Transplantation for Ischemic Brain Injury(——A Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of hNPC01 Injection Derived from Human Induced Pluripotent Stem Cells in Improving Hemiplegic Sequelae of Ischemic Stroke)(Phase I) | iPSC | Heart | Human Neural Precursor Cell (hNPC) | China | 2023-10-31 |
| 72 | Phase IIa Clinical Study of Human Neural Precursor Cell (hNPC) Transplantation for Ischemic Brain Injury ——A Phase IIa Clinical Study to Evaluate the Safety, | iPSC | Heart | Human Neural Precursor Cell | China | 2025-06-10 |

| | | | | | | |
|---|---|---|---|---|---|---|
| | Tolerability, and Efficacy of hNPC01 Injection Derived from Human Induced Pluripotent Stem Cells in Improving Hemiplegic Sequelae of Ischemic Stroke | | | | | |
| 73 | A Prospective Study on Induced Pluripotent Stem Cell-Derived Exosomes for the Treatment of Diabetic Peripheral Neuropathy | iPSC | Diabetes/nervous system | Exosomes | China | 2025-09-08 |
| 74 | Stereotactic Intracerebral Injection of IPSC-DAPs in Patients with Parkinson's Disease | iPSC | PD/nervous system | dopaminergic neuron | China | 2025-05-15 |
| 75 | A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older with Retinitis Pigmentosa | iPSC | Eye | retina | USA | 2026-04-16 |
| 76 | A Study To Evaluate The Safety Of A Delivery Device For Administering LCTOPC1 In Participants With Spinal Cord Injury (DOSED) | ESC | Spinal cord/nervous system | oligodendrocyte precursor cell | USA | 2025-04-30 |
| 77 | A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) (CLARICO) | iPSC | Eye | photoreceptor cell | USA | 2025-03-10 |
| 78 | A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease | iPSC | Lung | mesenchymal stromacell | China | 2025-03-01 |
| 79 | Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops For The Treatment Of Stable Vitiligo | iPSC | Immune System/Blood | Exosomes | China | 2025-02-05 |
| 80 | The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia | not specified | Neoplasia/blood | natural killer cell | China | 2025-02-01 |
| 81 | Exploratory Study on the Treatment of Moderate to Severe Acute Respiratory Distress Syndrome in Children with Exosomes Derived from Induced Pluripotent Stem Cells (iPSC-Exo) | iPSC | Neoplasia/blood | Exosomes | China | 2025-01-01 |
| 82 | IPSC-Derived CTL Therapy For Cervical Cancer: Phase I Clinical Trial (IPSC-Derived CTL Therapy For Cervical Cancer: Phase I Clini | iPSC | Neoplasia/solid cervix | cytotoxic T cell | Japan | 2024-12-27 |
| 83 | An open-label, single-center, first-in-human study to evaluate the safety, tolerability and activity of autologous human induced pluripotent | iPSC | Vasculature | endothelial cell | South Korea | 2024-12-20 |

| | | | | | | |
|---|---|---|---|---|---|---|
| | stem cell derived endothelial cells (hiPSC-ECs) in patients with peripheral artery disease | | | | | |
| 84 | A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects with Parkinson's Disease | iPSC | PD/nervous system | dopaminergic neuron | USA | 2024-12-18 |
| 85 | Ph I Trial of Cell Based Therapy for DMD | iPSC | DMD/muscle | Muscle progenitor cell | USA | 2024-12-16 |
| 86 | Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons | iPSC | PD/nervous system | dopaminergic neuron | USA | 2025-04-29 |
| 87 | Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia (iNK-r/r AML) | iPSC | Neoplasia/blood | natural killer cell | China | 2024-11-25 |
| 88 | A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) | ESC | Brain/nervous system | interneuron | USA | 2024-11-14 |
| 89 | A PHASE IIB, RANDOMIZED, ASSESSOR-MASKED, MULTICENTER CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF SUBRETINAL IMPLANTATION OF THE CPCB-RPE1 IMPLANT IN SUBJECTS WITH ADVANCED, DRY AMD (GEOGRAPHIC ATROPHY) (PATCH-AMD) | ESC | Eye | retinal pigment epithelial cell | USA | 2024-10-01 |
| 90 | The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease | iPSC | PD/nervous system | dopaminergic neuron | China | 2024-08-23 |
| 91 | Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease | iPSC | PD/nervous system | dopaminergic neuron | USA | 2024-08-07 |
| 92 | A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (CALiPSO-1) (CALiPSO-1) | iPSC | Immune System/Blood | natural killer cell | USA | 2025-02-06 |
| 93 | Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia | iPSC | Immune System/Blood | natural killer cell | USA | 2024-07-15 |
| 94 | Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | iPSC | Neoplasia/solid ovary | natural killer cell | USA | 2024-07-11 |
| 95 | Clinical study to evaluate the safety and efficacy of human-induced pluripotent stem cell-derived platelets in patients with acute leukemia undergoing | iPSC | Immune System/Blood | platelet | China | 2024-07-02 |

| | | | | | | |
|---|---|---|---|---|---|---|
| | chemotherapy-induced thrombocytopenia | | | | | |
| 96 | Follow-up study of human induced Pluripotent Stem (iPS) cell-derived cardiomyocyte spheroids in patients with severe heart failure, secondary to ischemic heart disease, undergoing coronary artery bypass grafting | iPSC | Heart | cardiac muscle cell | Japan | 2024-06-13 |
| 97 | Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II) CT1-DAP001 | iPSC | PD/nervous system | dopaminergic neuron | USA | 2024-06-01 |
| 98 | The Effect of GD-iExo-003 in Acute Ischemic Stroke ExoCURE | iPSC | Heart | Exosomes | China | 2024-06-05 |
| 99 | Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia | iPSC | Neoplasia/blood | natural killer cell | China | 2024-04-30 |
| 100 | Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration | iPSC | Eye | retinal pigment epithelial cell | India | 2024-04-06 |
| 101 | FT819 in Moderate to Severe Active Systemic Lupus Erythematosus | iPSC | Immune System/Blood | T cell | USA | 2024-03-28 |
| 102 | Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS) (iPSC-MNP) | iPSC | Nervous system | neural stem cell | China | 2024-03-13 |
| 103 | A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD | iPSC | Immune System/Blood | mesenchymal stroma cell | China | 2024-02-10 |
| 104 | A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor | iPSC | Neoplasia/solid | natural killer cell | China | 2024-02-01 |
| 105 | A Trial to Evaluate the Safety, Tolerability, and Efficacy of NCR100 Injection in the Treatment of Subjects With KOA (NCR100) | iPSC | Musculoskeletal/cartilage | mesenchymal stroma cell | China | 2024-01-25 |
| 106 | Phase 1/2a Study of ANPD001 in Parkinson Disease (ASPERO) | iPSC | PD/nervous system | dopaminergic neuron | USA | 2024-01-23 |
| 107 | The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease | iPSC | PD/nervous system | dopaminergic neuron | China | 2024-01-17 |
| 108 | FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | iPSC | Neoplasia/solid | T cell | USA | 2024-01-05 |

| | | | | | | |
|---|---|---|---|---|---|---|
| 109 | Retinal Pigment Epithelium Safety Study For Patients In B4711001 | ESC | Eye | retinal pigment epithelial cell | USA | 2024-01-01 |
| 110 | Safety and Feasibility of DopaCell transplantation in patients with Parkinson's disease | ESC | PD/nervous system | dopaminergic neuron | Iran | 2023-12-22 |
| 111 | A single-center, phase 1/2a clinical trial to evaluate the safety, maximum tolerated dose, and exploratory efficacy of MR-MC-01 treatment in patients with underactive bladder | ESC | Bladder | mesenchymal stroma cell | South Korea | 2023-12-15 |
| 112 | Phase II clinical trial of CAStem cell injection in the treatment of acute graft-versus-host disease | ESC | Immune System/Blood | M-cells | China | 2023-12-01 |
| 113 | Clinical trial of human (allogeneic) iPS cell-derived cardiomyocytes sheet for dilated cardiomyopathy | iPSC | Heart | cardiac muscle cell | Japan | 2023-11-25 |
| 114 | A Clinical Trial of Parkinson's Disease Treatment by hiPSCs Derived Dopaminergic Neural Precursor Cells | iPSC | PD/nervous system | dopaminergic neuron | China | 2023-11-23 |
| 115 | FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) | iPSC | Neoplasia/blood | natural killer cell | USA | 2023-11-16 |
| 116 | A Safety and Tolerability Study of Human Forebrain Neural Progenitor Cells Injection (hNPC01) in Subjects With Chronic Ischemic Stroke | iPSC | Heart | neural stem cell | China | 2023-11-09 |
| 117 | Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM) | iPSC | Neoplasia/solid Brain | natural killer cell | China | 2023-10-29 |
| 118 | A Phase I/II Study of Evaluate the Safety and Efficacy of HLCR011 in Patients with Retinal Pigment Epithelium Tear | iPSC | Eye | retinal pigment epithelial cell | Japan | 2023-10-18 |
| 119 | Efficacy and safety of CAStem cell injection in the treatment of acute exacerbation of interstitial lung disease (AE-ILD) | ESC | Lung | M-cells | China | 2023-09-21 |
| 120 | Long Term Follow-up of Patients With Parkinson's Disease Who Had Administered of A9-DPC in SB-PD-001 Study | ESC | PD/nervous system | dopaminergic neuron | South Korea | 2023-09-14 |
| 121 | Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure | iPSC | Heart | cardiac muscle cell | USA | 2023-09-05 |
| 122 | A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD | iPSC | Immune System/Blood | Mesenchymal Stem Cell | Australia | 2024-03-04 |

| | | | | | | |
|---|---|---|---|---|---|---|
| 123 | Safety and Efficacy of MCA-derived Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients: The Nereid Study* | iPSC | Immune System/Blood | mesenchymal stem cell | Netherlands | 2023-07-01 |
| 124 | An exploratory clinical study of islet-like cell transplantation differentiated from autologous induced pluripotent stem cells for the treatmen of type 1 diabetes | iPSC | Diabetes/islets | progenitor cell of endocrine pancreas | China | 2023-06-11 |
| 125 | Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Refractory Focal Epilepsy | iPSC | Nervous system | Exosomes | China | 2023-06-05 |
| 126 | Treatment of Non-ischemic Cardiomyopathies by Intravenous Extracellular Vesicles of Cardiovascular Progenitor Cells (SECRET-HF) | ESC | Heart | cardioblast | France | 2023-05-31 |
| 127 | Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01 | ESC | PD/nervous system | dopaminergic neuron | USA | 2023-05-16 |
| 128 | A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | ESC | Diabetes/islets | progenitor cell of endocrine pancreas | USA | 2023-05-16 |
| 129 | Study to Evaluate the Safety and Efficacy of ESC-derived Dopamine Progenitor Cell Therapy in PD Patients | ESC | PD/nervous system | dopaminergic neuron | South Korea | 2023-05-09 |
| 130 | Observational study one year after transplantation of iPS cell-derived neural precursor/stem cells for spinal cord injury | iPSC | Nervous system | neural stem cell | Japan | 2023-05-01 |
| 131 | Combination therapy of iPS-NKT cell and DC/Gal (Combination therapy of iPS-NKT cell and DC/Gal) | iPSC | Neoplasia/solid head and neck | natural killer cell | Japan | 2023-05-01 |
| 132 | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | iPSC | Neoplasia/solid ovary | natural killer cell | USA | 2023-04-28 |
| 133 | Induced Pluripotent Stem Cell Derived Exosomes for the Treatment of Atopic Dermatitis | iPSC | Immune System/Blood | Exosomes | China | 2023-04-12 |
| 134 | A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | ESC | Eye | retinal pigment epithelial cell | USA | 2023-03-24 |
| 135 | Safety and Efficacy of Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops Treatment for Dry Eye Diseases Post Refractive | not specified | Eye | mesenchymal stroma cell | China | 2023-03-01 |

| | | | | | | |
|---|---|---|---|---|---|---|
| | Surgery and Associated With Blepharospasm | | | | | |
| 136 | Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease | iPSC | Heart | cardiac muscle cell | Japan | 2023-02-03 |
| 137 | A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (ELiPSE-1) | iPSC | Neoplasia/blood | natural killer cell | USA | 2023-01-24 |
| 138 | IPS Differentiated Cardiomyocytes Vein Transplantation for Chronic Heart Failure (IDCVTCHF) | iPSC | Heart | cardiac muscle cell | China | 2022-12-31 |
| 139 | Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia | iPSC | Neoplasia/blood | natural killer cell | China | 2022-12-24 |
| 140 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | iPSC | Neoplasia/blood | natural killer cell | USA | 2022-12-01 |
| 141 | A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease (STEM-PD) | ESC | PD/nervous system | dopaminergic neuron | Sweden | 2022-11-30 |
| 142 | Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia | iPSC | Neoplasia/blood | natural killer cell | China | 2022-10-28 |
| 143 | Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure | iPSC | Heart | cardiac muscle cell | USA | 2022-10-09 |
| 144 | Safety and Tolerability of IMMUNA(IMM01-STEM) in Patients With Muscle Atrophy Related to Knee Osteoarthritis | not specified | Musculoskeletal | Secretome | USA | 2022-09-13 |
| 145 | Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration | iPSC | Eye | retinal pigment epithelial cell | China | 2022-08-01 |
| 146 | Treating Heart Failure With hiPSC-CMs | iPSC | Heart | cardiac muscle cell | USA | 2022-06-30 |
| 147 | Clinical trial of human (allogeneic) iPS cell-derived cardiomyocytes sheet for ischemic cardiomyopathy (Follow-up trial) | iPSC | Heart | cardiac muscle cell | Japan | 2022-06-22 |
| 148 | FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy | ESC | Brain/nervous system | interneuron | USA | 2022-06-16 |
| 149 | Evaluation of knee function and safety after treatment of knee articular cartilage damage with iPS-cell-derived cartilage | iPSC | Musculoskeletal/cartilage | cartilage tissue | Japan | 2022-06-16 |
| 150 | A study on the effectiveness and safety of CAStem cell injection in the treatment of acute | ESC | Immune System/lung | M-cells | China | 2022-06-10 |

| | | | | | | |
|---|---|---|---|---|---|---|
| | respiratory distress syndrome | | | | | |
| 151 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | iPSC | Neoplasia/solid | natural killer cell | USA | 2022-05-31 |
| 152 | A prospective observational study of Induced Pluripoteint Stem Cell-derived Cardiac Spheres transplantation EXTENDed Follow-up | iPSC | Heart | cardiac muscle cell | Japan | 2022-04-01 |
| 153 | Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction (HECTOR) | ESC | Heart | cardiac muscle cell | USA | 2022-03-22 |
| 154 | Clinical Research of allogeneic iPSC-RPE cell strip transplantation for RPE impaired disease (CR of aiPSC-RPE CSt transplantation forRID) | iPSC | Eye | retinal pigment epithelial cell | Japan | 2022-02-22 |
| 155 | The safety, tolerability, and preliminary efficacy of CAStem injection intravenously injected into the knee for meniscus injury in Chinese subjects | ESC | Musculoskeletal/meniscus | M-cells | China | 2022-02-21 |
| 156 | An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D | ESC | Diabetes/islets | progenitor cell of endocrine pancreas | USA | 2022-01-24 |
| 157 | Clinical study on the safety and efficacy of human embryonic stem cell-derived retinal pigment epithelial cells transplantation for the treatment of macular hole of high myopia | ESC | Eye | retinal pigment epithelial cell | China | 2022-01-15 |
| 158 | Safety, Tolerability and Efficacy of CYP-006TK in Adults With Diabetic Foot Ulcers | iPSC | Immune System/skin | mesenchymal stroma cell | Australia | 2022-01-04 |
| 159 | A Clinical Research on the Safety of Hepatocytes Therapy Generated from Human Embryonic Stem Cells for Patients with Acute or Acute-on-Chronic Liver Failure | ESC | Liver | hepatocyte | China | 2022-01-01 |
| 160 | Regenerative medicine for spinal cord injury at subacute stage using human induced pluripotent stem cell-derived neural stem/progenitor cells | iPSC | Spinal cord/nervous system | neural stem cell | Japan | 2021-12-07 |
| 161 | FT576 in Subjects With Multiple Myeloma | iPSC | Neoplasia/blood | natural killer cell | USA | 2021-11-24 |
| 162 | Natural Killer (NK) Cell Therapy for B-Cell Malignancies | iPSC | Neoplasia/blood | natural killer cell | China | 2021-11-04 |
| 163 | FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia | iPSC | Neoplasia/blood | natural killer cell | USA | 2021-11-03 |

| | | | | | | |
|---|---|---|---|---|---|---|
| 164 | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | iPSC | Neoplasia/solid | natural killer cell | USA | 2021-10-15 |
| 165 | A Study Of Implantation Of Retinal Pigment Epithelium In Subjects With Acute Wet Age Related Macular Degeneration | ESC | Eye | retinal pigment epithelial cell | UK | 2021-10-14 |
| 166 | Treating Heart Failure With hPSC-CMs (HEAL-CHF) | iPSC | Heart | cardiac muscle cell | USA | 2021-10-08 |
| 167 | phase 1/2a clinical study to evaluate the safety and exploratory efficacy for PSA-NCAM (+) NPC | ESC | Spinal cord/nervous system | neural progenitor cell | South Korea | 2021-09-23 |
| 168 | Treating Congestive HF With hiPSC-CMs Through Endocardial Injection | iPSC | Heart | cardiac muscle cell | USA | 2021-09-21 |
| 169 | A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis | ESC | Immune System | mesenchymal stroma cell | China | 2021-08-31 |
| 170 | MEG-002: Exploratory clinical study in thrombocytopenic patients | iPSC | Immune System/Blood | platelet | Japan | 2021-08-19 |
| 171 | FT819 in Subjects With B-cell Malignancies | iPSC | Neoplasia/blood | T cell | USA | 2021-07-26 |
| 172 | iPS cell-derived corneal endothelial cell substitutes for bullous keratopathy | iPSC | Vasculature | corneal endothelial cell | Japan | 2021-07-15 |
| 173 | A phase I/II study of human induced Pluripotent Stem (iPS) cell-derived cardiomyocyte spheroids in patients with severe heart failure, secondary to ischemic heart disease, undergoing coronary artery bypass grafting (LAPiS Study) | iPSC | Heart | cardiac muscle cell | Japan | 2022-04-19 |
| 174 | A phase 1 clinical trial of intraperitoneal administration of iCAR-ILC/N101 for ovarian clear cell carcinoma | iPSC | Neoplasia/solid ovary | natural killer cell | Japan | 2021-05-10 |
| 175 | Phase 1 Study To Assess the Safety and Tolerability of Human Embryonic Stem Cell-Derived Midbrain Dopamine Neuron | ESC | PD/nervous system | dopaminergic neuron | USA | 2021-05-03 |
| 176 | FT516 and IL2 With Enoblituzumab for Ovarian Cancer | iPSC | Neoplasia/solid ovary | natural killer cell | USA | 2021-04-02 |
| 177 | A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | ESC | Diabetes/islets | progenitor cell of endocrine pancreas | USA | 2021-03-29 |
| 178 | Stem cell therapy in knee osteoarthritis | iPSC | Musculoskeletal/immune system | mesenchymal stroma cell | Australia | 2021-03-15 |
| 179 | Clinical Research of allogeneic iPSC-RPE cell suspension transplantation for RPE impaired disease (CR of aiPSC-RPE CS transplantation forRID) | iPSC | Eye | retinal pigment epithelial cell | Japan | 2021-03-01 |
| 180 | A Clinical Trial to Evaluate the Effects of Autologous induced Pluripotent Stem | iPSC | Neoplasia/solid breast | natural killer cell | Iran | 2021-02-18 |

| | | | | | | |
|---|---|---|---|---|---|---|
| | Cell-Derived Natural Killer Cells in Personalized Treatment of Patients with Advanced Metastatic Breast Cancer | | | | | |
| 181 | A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS) | ESC | Heart | neural stem cell | USA | 2021-01-04 |
| 182 | Development of treatment of knee articular cartilage damage with iPS-cell-derived cartilage. (Development of treatment of knee articular cartilage damage with iPS-cell-derived cartilage.) | iPSC | Musculoskeletal/cartilage | cartilage tissue | Japan | 2020-11-11 |
| 183 | Safety study of induced pluripoteint stem cell-derived cardiac spheres transplantation (IPSCS study) | iPSC | Heart | cardiac muscle cell | Japan | 2020-11-09 |
| 184 | Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis | ESC | Bladder | mesenchymal stroma cell | South Korea | 2020-10-20 |
| 185 | FT538 in Subjects With Advanced Hematologic Malignancies | iPSC | Neoplasia/blood | natural killer cell | USA | 2020-10-17 |
| 186 | Safety Study of allogenic hiPSC-retinas in Retinitis Pigmentosa | iPSC | Eye | retina | Japan | 2020-10-05 |
| 187 | Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration | iPSC | Eye | retinal pigment epithelial cell | USA | 2020-09-23 |
| 188 | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL | iPSC | Neoplasia/blood | natural killer cell | USA | 2020-09-22 |
| 189 | A Phase I study of iPS-NKT cell intra-arterial infusion therapy in patients with recurrent or advanced head and neck cancer | iPSC | Neoplasia/solid head and neck | natural killer cell | Japan | 2020-09-11 |
| 190 | FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | iPSC | Neoplasia/solid | natural killer cell | USA | 2020-09-07 |
| 191 | The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause (MEND) | iPSC | Immune System | mesenchymal stroma cell | Australia | 2020-08-24 |
| 192 | Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia | iPSC | Immune System | natural killer cell | USA | 2020-05-14 |
| 193 | Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment | ESC | Eye | retinal pigment epithelial cell | China | 2020-05-01 |

| | | | | | | |
|---|---|---|---|---|---|---|
| | Epitheliums in Treatment of Retinitis Pigmentosa | | | | | |
| 194 | Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia (COVID-19) | ESC | Immune System | mesenchymal stroma cell | China | 2020-03-20 |
| 195 | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | iPSC | Neoplasia/blood | natural killer cell | USA | 2020-03-19 |
| 196 | Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure (BioVAT-HF) | iPSC | Heart | cardiac muscle cell | Germany | 2020-02-03 |
| 197 | Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS | ESC | Immune System | mesenchymal stroma cell | China | 2020-01-27 |
| 198 | Clinical study of human (allogeneic) iPS cell-derived cardiomyocyte sheet for ischemic cardiomyopathy | iPSC | Heart | cardiac muscle cell | Japan | 2020-01-10 |
| 199 | Clinical Safety Study of Human Embryonic Stem Cell Derived Mesenchymal Cells in the Treatment of Moderate and Severe Intrauterine Adhesions | ESC | Uterus | mesenchymal stroma cell | China | 2020-01-01 |
| 200 | Clinical Trial of Human (Allogeneic) iPS Cell-derived Cardiomyocytes Sheet for Ischemic Cardiomyopathy | iPSC | Heart | cardiac muscle cell | Japan | 2019-12-02 |
| 201 | FT516 in Subjects With Advanced Hematologic Malignancies | iPSC | Neoplasia/blood | natural killer cell | USA | 2019-10-04 |
| 202 | Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy | iPSC | Neoplasia/blood | natural killer cell | USA | 2019-10-04 |
| 203 | Interventional Study of Implantation of hESC-derived RPE in Patients With RP Due to Monogenic Mutation | ESC | Eye | dendritic cell, human | France | 2019-08-19 |
| 204 | Clinical trial of human (allogeneic) induced pluripotent stem cell-derived cardiomyocyte sheet for severe cardiomyopathy | iPSC | Heart | cardiac muscle cell | Japan | 2019-08-11 |
| 205 | A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus (VC01-103) | ESC | Diabetes/islets | progenitor cell of endocrine pancreas | USA | 2019-06-25 |
| 206 | Long-term, Non-interventional, Observational Study Following Treatment With | iPSC | Neoplasia/solid | natural killer cell | USA | 2019-06-11 |

| | | | | | | |
|---|---|---|---|---|---|---|
| | Fate Therapeutics FT500 Cellular Immunotherapy | | | | | |
| 207 | First-in-human clinical research of iPS derived corneal epithelial cell sheet transplantation for patients with limbal stem-cell deficiency | iPSC | Eye | corneal epithelial cell | Japan | 2019-05-23 |
| 208 | iPSC-derived platelet transfusion trial1 (iPLAT1) | iPSC | Immune System/Blood | platelet | Japan | 2019-05-14 |
| 209 | Mesenchymal Stem Cells (MSCs) - Like Cell Transplantation in Women With Primary Ovarian Insufficiency (MSCLCTWPOI) | ESC | Ovary | mesenchymal stroma cell | China | 2019-04-03 |
| 210 | A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke | iPSC | Heart | neural stem cell | China | 2019-03-01 |
| 211 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | iPSC | Neoplasia/solid | natural killer cell | USA | 2019-02-15 |
| 212 | A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells | iPSC | PD/nervous system | neural stem cell | China | 2019-02-01 |
| 213 | Safety Observation on hESC Derived MSC Like Cell for the Meniscus Injury | ESC | Musculoskeletal/meniscus | mesenchymal stroma cell | China | 2019-01-04 |
| 214 | A Study of Autologous Induced Islet Body With Type 1 Diabetes | iPSC | Diabetes/islets | islet of Langerhans | China | 2019-01-01 |
| 215 | iHSCs With the Gene Correction of HBB Intervent Subjests With β-thalassemia Mutations | iPSC | Immune System/Blood | hematopoietic stem cell | China | 2019-01-01 |
| 216 | A Clinical Study of iEPC Intervent Subjects With Cerebral Hemorrhagic Stroke | iPSC | Heart | Endothelial Progenitor Cell | China | 2018-12-01 |
| 217 | Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases | ESC | Eye | retinal pigment epithelial cell | China | 2018-10-01 |
| 218 | Kyoto Trial to Evaluate the Safety and Efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease | iPSC | PD/nervous system | dopaminergic neuron | Japan | 2018-08-01 |
| 219 | Kyoto Trial to Evaluate the Safety and Efficacy of Tacrolimus in the iPSC-based Therapy for Parkinson's Disease | iPSC | PD/nervous system | dopaminergic neuron | Japan | 2018-08-01 |
| 220 | A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration Secondary | ESC | Eye | retinal pigment epithelial cell | Japan | 2018-07-13 |

| | | | | | | |
|---|---|---|---|---|---|---|
| | to Dry Age-related Macular Degeneration | | | | | |
| 221 | AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer | ESC | Neoplasia/solid lung | dendritic cell, human | UK | 2018-06-01 |
| 222 | Clinical study of HAES transplantation in patients with neonatal onset urea cycle disorder | ESC | Liver | hepatocyte | Japan | 2018-04-30 |
| 223 | A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS) | ESC | Nervous system | astrocyte | Israel | 2018-04-12 |
| 224 | A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy | ESC | Eye | retinal pigment epithelial cell | Japan | 2018-01-08 |
| 225 | Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Clinical-grade Human Embryonic Stem Cells | ESC | Eye | retinal pigment epithelial cell | China | 2017-09-06 |
| 226 | A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness | ESC | Diabetes/islets | progenitor cell of endocrine pancreas | USA | 2017-07-06 |
| 227 | A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus | ESC | Diabetes/islets | progenitor cell of endocrine pancreas | USA | 2017-07-05 |
| 228 | Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease | ESC | PD/nervous system | dopaminergic neuron | China | 2017-05-01 |
| 229 | A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease | iPSC | Immune System | mesenchymal stroma cell | Australia | 2017-03-01 |
| 230 | A Study of transplantation of allogenic induced pluripotent stem cell (iPSC) derived retinal pigment epithelium (RPE) cell suspension in subjects with neovascular age related macular degeneration | iPSC | Eye | retinal pigment epithelial cell | Japan | 2017-02-06 |
| 231 | One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™ | ESC | Diabetes/islets | progenitor cell of endocrine pancreas | USA | 2016-11-07 |
| 232 | A Study to Evaluate the Safety of Neural Stem | other (parthenogenetic PSC) | PD/nervous system | neural stem cell | Australia | 2016-07-01 |

| | | | | | | |
|---|---|---|---|---|---|---|
| | Cells in Patients With Parkinson's Disease | | | | | |
| 233 | The Safety and Tolerability of Sub-retinal Transplantation of SCNT-hES-RPE Cells in Patients With Advanced Dry AMD | ESC (SCNT) | Eye | mesenchymal stroma cell | South Korea | 2016-05-01 |
| 234 | Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD | ESC | Eye | retinal pigment epithelial cell | USA | 2016-02-16 |
| 235 | The clinical trial of human embryonic stem cell derived epithelial cells transplantation in the treatment of severe ocular surface diseases | ESC | Eye | corneal epithelial cell | China | 2015-10-01 |
| 236 | Clinical study of subretinal transplantation of clinical human embryo stem cell derived retinal pigment epitheliums in treatment of retinitis pigmento diseases | ESC | Eye | retinal pigment epithelial cell | China | 2015-09-20 |
| 237 | Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD (PORTRAY) | ESC | Eye | retinal pigment epithelial cell | Japan | 2015-08-24 |
| 238 | Stem Cell Therapy for Outer Retinal Degenerations | ESC | Eye | retinal pigment epithelial cell | Brazil | 2015-08-01 |
| 239 | Clinical study of subretinal transplantation of human embryo stem cell derived retinal pigment epitheliums in treatment of macular degeneration diseases | ESC | Eye | retinal pigment epithelial cell | China | 2015-05-01 |
| 240 | Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration | ESC | Eye | retinal pigment epithelial cell | Switzerland | 2015-04-01 |
| 241 | Dose Escalation Study of AST-OPC1 in Spinal Cord Injury | ESC | Spinal cord/nervous system | oligodendrocyte precursor cell | USA | 2015-03-01 |
| 242 | Thalassemia Treatment Based on the Stem Cell Technology | iPSC | Immune System/Blood | hematopoietic stem cell | China | 2015-01-01 |
| 243 | A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus | ESC | Diabetes/islets | progenitor cell of endocrine pancreas | USA | 2014-09-01 |
| 244 | A Study of transplantation of autologous induced pluripotent stem cell (iPSC) derived retinal pigment epithelium (RPE) cell sheet in subjects with exudative age related macular degeneration | iPSC | Eye | retinal pigment epithelial cell | Japan | 2013-10-02 |
| 245 | Transplantation of Human Embryonic Stem Cell-derived Progenitors in Severe Heart Failure (ESCORT) | ESC | Heart | cardioblast | France | 2013-05-27 |

| | | | | | | |
|---|---|---|---|---|---|---|
| 246 | Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration | ESC | Eye | retinal pigment epithelial cell | USA | 2013-03-01 |
| 247 | Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD | ESC | Eye | retinal pigment epithelial cell | Japan | 2013-02-25 |
| 248 | A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) | ESC | Eye | retinal pigment epithelial cell | Japan | 2013-01-16 |
| 249 | A Phase I/IIa, Open-Label, Single-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Advanced Dry Age-related Macular Degeneration (AMD) | ESC | Eye | retinal pigment epithelial cell | South Korea | 2012-09-01 |
| 250 | Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy (SMD) | ESC | Eye | retinal pigment epithelial cell | South Korea | 2012-09-01 |
| 251 | Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients | ESC | Eye | retinal pigment epithelial cell | Japan | 2012-07-11 |
| 252 | Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) | ESC | Eye | retinal pigment epithelial cell | Japan | 2011-12-13 |
| 253 | Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy | ESC | Eye | retinal pigment epithelial cell | Japan | 2011-06-16 |
| 254 | Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (Dry AMD) | ESC | Eye | retinal pigment epithelial cell | Japan | 2011-06-09 |
| 255 | Safety Study of GRNOPC1 in Spinal Cord Injury | ESC | Spinal cord/nervous system | oligodendrocyte precursor cell | USA | 2010-10-01 |